Review article: Spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 11, 2015, Pages 1116-1131

  Dever, J B ^a   Sheikh, M Y ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; ANTIINFECTIVE AGENT;

ASCITES FLUID ANALYSIS; BACTERIAL PERITONITIS; BACTERIUM CULTURE; BIFIDOBACTERIUM; CLINICAL CLASSIFICATION; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED INFECTION; DIET THERAPY; DISEASE ASSOCIATION; ENTEROCOCCUS; GENETIC RISK; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LACTOBACILLUS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; PARACENTESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STAPHYLOCOCCUS; SYSTEMATIC REVIEW; TREATMENT INDICATION; ASCITES; BACTERIAL INFECTIONS; COMPLICATION; CROSS INFECTION; LIVER CIRRHOSIS; MICROBIOLOGY; PERITONITIS; PROCEDURES; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ASCITES; BACTERIAL INFECTIONS; CROSS INFECTION; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PERITONITIS; RISK FACTORS;

EID: 84929103370     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13172     Document Type: Review

References (163)

1. Krencker E,. Bacterium coli commune als Sepsiserreger in 2 fallen von abdominaler krankungen. Munchen Med Wschr 1907; 54: 2095.
2. Caroli J, Platteborse R,. Portocaval septicemia; liver cirrhosis & septicemia caused by colibacillus. Sem Hop 1958; 34: 472-87.
3. Kerr DNS, Pearson DT, Read AE,. Infection of ascitic fluid in patients with hepatic cirrhosis. Gut 1963; 4: 394-8.
4. Conn HO,. Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms. A relatively common but rarely recognized syndrome. Ann Intern Med 1964; 60: 568-80.
5. Schrier RW, Arroyo V, Bernardi M, et al,. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
6. Runyon BA,. Spontaneous bacterial peritonitis associated with cardiac ascites. Am J Gastroenterol 1984; 79: 796.
7. Kato A, Ohtake T, Furuya R, et al,. Spontaneous bacterial peritonitis in an adult patient with nephritic syndrome. Intern Med 1993; 32: 719-21.
8. Makharia GK, Sharma BC, Bhasin DK, et al,. Spontaneous bacterial peritonitis in a patient with gastric carcinoma. J Clin Gastroenterol 1998; 27: 269-70.
9. Kurtz RC, Bronzo RL,. Does spontaneous bacterial peritonitis occur in malignant ascites? Am J Gastroenterol 1982; 77: 146-8.
10. Murray L, Lee YT,. Primary peritonitis: an unusual operative diagnosis. Am Surg 1989; 55: 710-3.
11. Lipsky PE, Hardin JA, Schour L, et al,. Spontaneous peritonitis and systemic lupus erythematosus. Importance of accurate diagnosis of gram-positive bacterial infections. JAMA 1975; 232: 929-31.
12. Skau T, Tegner Y,. Spontaneous peritonitis and rheumatoid arthritis-a case report. Acta Chir Scand 1986; 152: 317-8.
13. Hurwich DB, Lindor KD, Hay JE, et al,. Prevalence of peritonitis and the ascitic fluid protein concentration amoung chronic liver disease patients. Am J Gastroenterol 1993; 88: 1254-7.
14. Rimola A, Garcia-Tsao G, Navasa M, et al,. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32: 142-53.
15. Guarner C, Runyon BA,. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995; 3: 311-28.
16. Marchesi J, Shanahan F,. The normal intestinal microbiota. Curr Opin Infect Dis 2007; 20: 508-13.
17. Guarner C, Runyon BA, Young S, et al,. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-8.
18. Bauer TM, Steinbruckner B, Brinkman F, et al,. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.
19. Scarpellini E, Valenza V, Gabrielli M, et al,. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105: 323-7.
20. Runyon BA, Squier S, Borzio M,. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21: 792-6.
21. Bhuva M, Ganger D, Jensen D,. Spontaneous bacterial peritonitis: an update on evaluation, management, and prevention. Am J Med 1994; 97: 169-75.
22. Garcia-Tsao G,. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992; 21: 257-75.
23. Fernández J, Navasa M, Gõmez J, et al,. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
24. Novovic S, Semb S, Olsen H, et al,. First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage. Scand J Gastroenterol 2012; 47: 212-6.
25. Such J, Runyon BA,. Spontaneous bacterial peritonitis. Clin Infect Dis 1998; 27: 669-74.
26. Yakar T, Guclu M, Serin E, et al,. A recent evaluation of empirical cephalopsporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci 2010; 55: 1149-54.
27. Piroth L, Pechinot A, Minello A, et al,. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. Scand J Infect Dis 2009; 41: 847-51.
28. Piroth L, Pechinot A, Di Martino V, et al,. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis 2014; 14: 287.
29. Evans LT, Kim WR, Poterucha JJ, et al,. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37: 897-901.
30. Fernández J, Acevedo J, Castro M, et al,. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
31. Park YH, Lee HC, Song HG, et al,. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18: 927-33.
32. Reuken PA, Pletz MW, Baier M, et al,. Emergence of spontaneous bacterial peritonitis due to enterococci-risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther 2012; 35: 1199-208.
33. Dupeyron C, Campillo SB, Mangeney N, et al,. Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third generation cephalosporins in cirrhotic patients: a prospective assessment of hospital acquired infections. Infect Control Hosp Epidemiol 2001; 22: 427-32.
34. Campillo B, Richardet JP, Kheo T, et al,. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002; 35: 1-10.
35. Choi JP, Lee SO, Kwon HH,. Clinical significance of spontaneous aeromonas bacterial peritonitis in cirrhotic patients: a matched case-control study. Clin Infect Dis 2008; 47: 66-72.
36. Jayasinghe S, Connor M, Donaldson S, et al,. Spontaneous bacterial peritonitis due to Listeria monocytogenes: importance of enrichment culture. J Clin Pathol 2010; 63: 835-6.
37. Horner R, Salla A, Oliveira LO, et al,. Spontaneous bacterial peritonitis caused by Streptococcus bovis: case report and review of the literature. Braz J Infect Dis 2010; 14: 294-6.
38. Dlamini NR, Bhamjee A, Levick P, et al,. Spontaneous bacterial peritonitis and pneumonia caused by Bordetella bronchiseptica. J Infect Dev Ctries 2012; 23: 588-91.
39. Singh N, Wagener MM, Gayoski T,. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at liver transplant unit. Clin Microbiol Infect 2003; 9: 531-7.
40. Hey P, Gow P, Torresi J, et al,. Cirrhosis, cellulitis and cats: a 'purrfect' combination for life-threatening spontaneous bacterial peritonitis from Pasteurella multocida. BMJ Case Rep 2012; Rep.10.1136/bcr-2012-007397.
41. Kim HM, Chon CY, Ahn SH, et al,. Fatal Spontaneous bacterial peritonitis by Leclercia adecarboxylata in a patient with hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1296-8.
42. Adhikary R, Joshi S, Venugopa RV, et al,. Spontaneous bacterial peritonitis caused by S. paratyphi A. J Assoc Physicians India 2013; 61: 930-1.
43. Runyon BA, Hoefs JC,. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 1984; 4: 447-50.
44. Runyon BA, Hoefs JC,. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 1984; 4: 1209-11.
45. Runyon BA, Canawati HN, Akriviadis EA,. Optimisation of ascitic fluid culture technique. Gastroenterology 1988; 95: 1351-5.
46. Caly WR, Strauss E,. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-8.
47. Fernandez J, Navasa M, Planas R, et al,. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
48. Carey WD, Boayke A, Leatherman J,. Spontaneous bacterial peritonitis: clinical and laboratory features with reference to hospital-acquired cases. Am J Gastroenterol 1986; 81: 1156-61.
49. Angeloni S, Nicolini G, Merli M, et al,. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003; 98: 1844-8.
50. Cereto F, Genescà J, Segura R,. Validation of automated blood cell counters for the diagnosis of spontaneous bacterial peritonitis. Am J Gastroenterol 2004; 99: 1400.
51. van de Geijn GJ, van Gent M, van Pul-Bom N, et al,. A new flow cytometric method for differential cell counting in ascitic fluid. Cytometry B Clin Cytom 2014; doi: 10.1002/cyto.b.21171. [Epub ahead of print].
52. Levy M, Tournot F, Muller C, et al,. Evaluation of screening tests for urinary infection in hospital patients. Lancet 1989; 2: 384-5.
53. Hiscoke C, Yoxall H, Greig D, et al,. Validation of a method for the rapid diagnosis of urinary tract infection suitable for use in general practice. Br J Gen Pract 1990; 40: 403-5.
54. Nousbaum JB, Cadranel JF, Nahon P, et al,. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007; 45: 1275-81.
55. Parsi MA, Saadeh SN, Zein NN, et al,. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology 2008; 135: 803-7.
56. Riggio O, Marzano C, Angeloni S, et al,. Do we really need alternatives to polymorphonuclear cells counting in ascitic fluid? Gastroenterology 2009; 136: 728-9.
57. Runyon BA,. AASLD practice guidelines: management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.
58. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
59. Orman ES, Hayashi PH, Bataller R, et al,. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol 2014; 12: 496-503.
60. Kim JJ, Tsukamoto MM, Mathur AK, et al,. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol 2014; 109: 1436-42.
61. Castellote J, Girbau A, Maisterra S, et al,. Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic outpatients undergoing large-volume paracentesis. J Gastroenterol Hepatol 2008; 23: 256-9.
62. Runyon BA,. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146: 2259-61.
63. Runyon BA,. Ascites and spontaneous bacterial peritonitis. In:, Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th edn. Philadelphia, PA: Saunders, 2006; 1935-64.
64. De Gottardi A, Thévenot T, Spahr L, et al,. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7: 906-9.
65. Sekiguchi H, Suzuki J, Daniels CE,. Making paracentesis safer: a proposal for the use of bedside abdominal and vascular ultrasonography to prevent a fatal complication. Chest 2013; 143: 1136-9.
66. Mercaldi CJ, Lanes SF,. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest 2013; 143: 532-8.
67. Grabau CM, Crago SF, Hoff LK, et al,. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 484.
68. Runyon BA, Umland ET, Merlin T,. Inoculation of blood culture bottles with ascitic fluid. Improved detection of spontaneous bacterial peritonitis. Arch Intern Med 1987; 147: 73-5.
69. Chinnock B, Hendey GW,. Can clear ascitic fluid appearance rule out spontaneous bacterial peritonitis? Am J Emerg Med 2007; 25: 934-7.
70. Chinnock B, Gomez R, Hendey GW,. Peritoneal fluid cultures rarely alter management in patients with ascites. J Emerg Med 2011; 40: 21-4.
71. Runyon BA,. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343.
72. Andreu M, Sola R, Siges-Serra A, et al,. Risk factors for spontanenous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 1133-8.
73. Llach J, Rimola A, Navasa M, et al,. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724.
74. Putz-Bankuti C, Pilz S, Stojakovic T, et al,. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int 2012; 32: 845-51.
75. Anty R, Tonohouan M, Ferrari-Panaia P, et al,. Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. Clin Transl Gastroenterol 2014; 5: e56.
76. Tito L, Rimola A, Gines P, et al,. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31.
77. Huang CH, Lin CY, Sheen IS, et al,. Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. Liver Int 2011; 31: 184-91.
78. Bernard B, Cadranel JF, Valla D, et al,. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108: 1828-34.
79. Goulis J, Armonis A, Patch D, et al,. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-12.
80. Rimola A, Bory F, Teres J, et al,. Oral, non-absorbale antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463-7.
81. Pauwels A, Mostefa-Kara N, Debenes B, et al,. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996; 24: 802-6.
82. Garcia-Tsao G, Sanyal AJ, Grace ND, et al,. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Hepatology 2007; 46: 922-38.
83. Nischalke HD, Berger C, Aldenhoff K, et al,. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011; 55: 1010-6.
84. Appenrodt B, Grunhage F, Gentemann MG, et al,. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-33.
85. Lutz P, Berger C, Langhans B, et al,. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis 2014; 46: 1047-50.
86. Choi EJ, Lee HJ, Kim KO, et al,. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011; 46: 616-20.
87. Goel GA, Deshpande A, Lopez R, et al,. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10: 422-7.
88. Bajaj JS, Zadvornova Y, Heuman DM, et al,. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-4.
89. Deshpande A, Pasupuleti V, Thota P, et al,. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 235-42.
90. Trikudanathan G, Israel J, Cappa J, et al,. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011; 65: 674-8.
91. O'Leary JG, Reddy KR, Wong F, et al,. Long-term use of antibiotics and proton-pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 753-9.
92. Senzolo M, Cholongitas E, Burra P, et al,. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189-93.
93. Ge PS, Runyon BA,. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60: 643-53.
94. Sersté T, Melot C, Francoz C, et al,. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-22.
95. Mandorfer M, Bota S, Schwabl P, et al,. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-90.
96. Thuvulath PJ, Moss S, Thompson R,. Spontaneous bacterial peritonitis-In-hospital mortality, predictors of survival, and health care costs from 1988-1998. Am J Gastroenterol 2001; 96: 1232-6.
97. Khan J, Pikkarainen P, Karvonen AL, et al,. Ascites: aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. Scand J Gastroenterol 2009; 44: 970-4.
98. Follo A, Llovet JM, Navasa M, et al,. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-501.
99. Tandon P, Garcia-Tsao G,. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011; 9: 260-5.
100. Bac DL,. Spontaneous bacterial peritonitis: an indication for liver transplantation? Scand J Gastroenterol Suppl 1996; 218: 38-42.
101. Van Theil DH, Hassanein T, Gurakar A, et al,. Liver transplantation after an acute episode of spontaneous bacterial peritonitis. Hepatogastroenterology 1996; 43: 1584-8.
102. Mounzer R, Malik SM, Nasr J, et al,. Spontaneous bacterial peritonitis before liver transplantation does not affect patient survival. Clin Gastroenterol Hepatol 2010; 8: 623-8.
103. Felisart J, Rimola A, Arroyo V, et al,. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457-62.
104. Runyon BA, McHutchison JG, Antillon MR, et al,. Short-course vs. long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled trial of 100 patients. Gastroenterology 1991; 100: 1737-42.
105. Navasa M, Follo A, Llovet JM, et al,. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111: 1011-7.
106. Runyon BA, Akriviadis EA, Sattler FR, et al,. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci 1991; 36: 1782.
107. Rimola A, Salmerõn JM, Clemente G, et al,. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21: 674-9.
108. Ricart E, Soriano G, Novella MT, et al,. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000; 32: 596-602.
109. França AV, De Souza JB, Silva CM, et al,. Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with ceftriaxone. J Clin Gastroenterol 2001; 33: 295-8.
110. Baskol M, Gursoy S, Baskol G, et al,. Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients. J Clin Gastroenterol 2003; 37: 403-5.
111. Cartier M, Terg R, Lucero R, et al,. Pilot study: gelafundin (polygeline) 4% plus antibiotics in the treatment of high-risk cirrhotic patients with spontaneous bacterial peritonitis. Aliment Pharmacol Ther 2010; 32: 43-8.
112. Mazer L, Tapper EB, Piatkowski G, et al,. The need for antibiotic stewardship and treatment standardization in the care of cirrhotic patients with spontaneous bacterial peritonitis-a retrospective cohort study examining the effect of ceftriaxone dosing. F1000Res 2014; 3: 57.
113. Cabrera J, Arroyo V, Ballesta AM, et al,. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82: 97.
114. Sambatakou H, Giamarellos-Bourboulis EJ, Galanakis N, et al,. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. Int J Antimicrob Agents 2001; 18: 441-4.
115. Esposito S, Noviello S, Leone S, et al,. Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study. J Chemother 2006; 18: 33-7.
116. Turnidge J,. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58: 29-36.
117. Terg R, Cobas S, Fassio E, et al,. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000; 33: 564-9.
118. Angeli P, Guarda S, Fasolato S, et al,. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006; 23: 75-84.
119. Dupeyron C, Mangeney N, Sedrati L, et al,. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38: 340-4.
120. Campillo B, Dupeyron C, Richardet JP, et al,. Epidemiology of severe hospital acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-70.
121. Jalan R, Schnurr K, Mookerjee RP, et al,. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-64.
122. Franch-Arcas G,. The meaning of hypoalbuminemia in clinical practice. Clin Nutr 2001; 20: 265-9.
123. Herrmann FR, Saqfran C, Levkoff SE, et al,. Serum albumin level on admission as a predictor of death, length of stay and readmission. Arch Intern Med 1992; 152: 125-30.
124. Sort P, Navasa M, Arroyo V, et al,. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
125. Signal SH, Stanca CM, Fernandez J, et al,. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597-9.
126. Saab S, Hernandez JC, Chi AC, et al,. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104: 993-1001.
127. Soriano G, Guarner C, Teixidõ M, et al,. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-81.
128. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al,. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding (Review). Cochrane Library 2010; 9: 1-67.
129. Novella M, Solà R, Soriano G, et al,. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25: 532-6.
130. Grangé JD, Roulot D, Pelletier G, et al,. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29: 430-6.
131. Terg R, Fassio E, Guevara M, et al,. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48: 774-9.
132. Singh N, Gayowski T, Yu VL, et al,. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122: 595-8.
133. Hanouneh MA, Hanouneh IA, Hashash JG, et al,. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46: 709-15.
134. Lutz P, Parcina M, Bekeredjian-Ding I, et al,. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS ONE 2014; 9: e93909.
135. Ginés P, Rimola A, Planas R, et al,. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 4: 716-24.
136. Lontos S, Gow PJ, Vaughan RB, et al,. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2008; 23: 252-5.
137. Inadomi J, Sonnenberg A,. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113: 1289-94.
138. Campillo B, Richardet J-P, Scherman E, et al,. Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. Nutrition 2003; 19: 515-21.
139. Casafont F, Sánchez E, Martín L, et al,. Influence of malnutrition on the prevalence of bacterial translocation and spontaneous bacterial peritonitis in experimental cirrhosis in rats. Hepatology 1997; 25: 1334.
140. Nompleggi D, Bonkovsky H,. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994; 19: 518-33.
141. O'Brien A, Williams R,. Nutrition in end-stage liver disease: principles and practice. Gastroenterology 2008; 134: 1729-40.
142. Tuomisto S, Pessi T, Collin P, et al,. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 2014; 14: 40.
143. Loguercio C, Federico A, Tuccillo C, et al,. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver disease. J Clin Gastroenterol 2005; 39: 540-3.
144. Chiva M, Soriano G, Rochat I, et al,. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.
145. Wiest R, Garcia-Tsao G,. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
146. Bauer TM, Schwacha H, Steinbruckner B, et al,. Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: poor performance of the glucose breath hydrogen test. J Hepatol 2000; 32: 382-6.
147. Pande C, Kumar A, Sarin SK,. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur J Gastroenterol Hepatol 2012; 24: 831-9.
148. Borzio M, Salerno F, Piantoni L, et al,. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
149. Singal AK, Salameh H, Kamath PS,. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther 2014; 40: 105-12.
150. Castellote J, Girbau A, Ariza X, et al,. Usefulness of reagent strips for checking cure in spontaneous bacterial peritonitis after short-course treatment. Aliment Pharmacol Ther 2010; 31: 125-30.
151. Ariza X, Castellote J, Lora-Tamayo J, et al,. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-32.
152. Kamani L, Mumtaz K, Ahmed US, et al,. Outcomes in culture positive and culture negative ascitic fluid infection in patients with viral cirrhosis: cohort study. BMC Gastroenterol 2008; 8: 59.
153. Cheong HS, Kang CI, Lee JA, et al,. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 1230-6.
154. Cholongitas E, Papatheodoridis GV, Lahanas A, et al,. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int 2005; 25: 57-61.
155. Kim SU, Kim do Y, Lee CK, et al,. Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2010; 25: 122-8.
156. Marchesini G, Bianchi G, Merli M, et al,. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
157. Runyon BA, Antillon MR, Montano AA,. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 1989; 97: 158-62.
158. Anty R, Tonohouan M, Ferrari-Panaia P, et al,. Low levels of 25-hydroxy vitamin D are independently associated with the risk of bacterial infection in cirrhotic patients. Clin Transl Gastroenterol 2014; 29 (5): e56.
159. Badawy AA, Zaher TI, Sharaf SM, et al,. Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis. World J Gastroenterol 2013; 19: 1271-7.
160. Hoefs JC,. Increase in ascites white blood cell and protein concentrations during diuresis in patients with chronic liver disease. Hepatology 1981; 1: 249-54.
161. Jones SR,. The absolute granulocyte count in ascites fluid. An aid to the diagnosis of spontaneous bacterial peritonitis. West J Med 1977; 126: 344-6.
162. Simel D, Rennie D, eds. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. 1st ed. New York: McGraw-Hill Professional, 2009.
163. Gerding DN, Hall WH, Schierl EA,. Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis. Ann Intern Med 1977; 86: 708-13.